Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
    • Internet & Telecom
  • Toggle search form
  • [Research] ABL Bio (298380) – Mirae Asset Securities | BBB Shuttle Re-rating · IGF1R Competitiveness · ABL001 Data Readout / 2026-03-26 Research
  • [Research] SK hynix (000660 / SKHY) – Kiwoom | Server DRAM · eSSD · Earnings Upgrades / 2026-04-09 Research
  • [Research] Alteogen (196170) – Daishin Securities | Keytruda Qlex Commercial Milestones · RNA Modality Expansion · Platform Re-rating / 2026-08-10 Research
  • [Research] ABL Bio (298380) – Kiwoom Securities | ABL301 Deprioritization · ABL001 Valuation · Grabody B Validity / 2026-02-02 Research
  • [Research] KEPCO (015760 / KEP) – Daishin Securities | Overseas Nuclear Expansion · Nuclear Utilization Recovery · 2026 Earnings Growth / 2026-02-27 Research
  • [Research] Samsung Electronics (005930) – Hyundai Motor Securities | HBM4 Share · AIDC Capex · DRAM ASP / 2026-07-31 Research
  • [Research] LIG D&A (079550) – Kiwoom Securities | Defense Export Expansion · GR Turnaround · 2026E Upward / 2026-02-19 Research
  • [Research] Samsung SDI (006400) – Kiwoom Securities | ESS & BBU Momentum · Europe Market Share Recovery · 4Q26 Turnaround / 2026-04-29 Research

[Research] Samsung Electronics (005930) – Shinhan | Supply-Demand Imbalance · High-Value Mix Expansion · Target PBR Upgrade / 2026-05-21

Posted on 5월 21, 20268월 25, 2026 By ksb220805@gmail.com

Brokerage : Shinhan Securities

Analyst : Hyungtae Kim, Hyesus Song

Investment Rating : BUY (Maintained)

Target Price : KRW 550,000 (Upgraded)

Core Momentum : Sustained operational leverage expected through 2027 driven by structural supply shortages and accelerating 2H shipments of premium applications including HBM4 and SOCAMM2.

📊 1. [Valuation & Key Financial Metrics]

  • Rating & Target Price: BUY maintained; Target Price raised by +83.3% to KRW 550,000 (99.3% upside potential based on May 20, 2026 closing price of KRW 276,000)
  • Valuation Methodology: Target Price derived by applying a target PBR multiple of 4.0x (DRAM peer group average) to the 12MF BPS of KRW 138,989
  • Valuation Re-rating Factors: Additional memory price increases, earnings visibility secured via long-term contracts, enhanced shareholder returns (share buyback/cancellation, dividends), and resolution of labor-related uncertainties
  • Key Financial Metrics & Forecasts (2024 ~ 2028F):
    • 2024: Revenue KRW 300.87T, OP KRW 32.73T, Net Profit (Controlling) KRW 33.62T, PER 11.1x, ROE 9.0%, PBR 0.9x, EV/EBITDA 3.6x, DY 2.7%
    • 2025: Revenue KRW 333.61T, OP KRW 43.60T, Net Profit (Controlling) KRW 44.26T, PER 18.8x, ROE 10.8%, PBR 1.9x, EV/EBITDA 7.7x, DY 1.4%
    • 2026F: Revenue KRW 707.99T (+112.2% YoY), OP KRW 367.12T (+743.0% YoY), Net Profit (Controlling) KRW 284.11T, PER 6.5x, ROE 50.6%, PBR 2.6x, EV/EBITDA 3.5x, DY 0.6%
    • 2027F: Revenue KRW 870.22T, OP KRW 490.59T, Net Profit (Controlling) KRW 374.99T, PER 5.0x, ROE 44.2%, PBR 1.8x, EV/EBITDA 2.3x, DY 4.7%
    • 2028F: Revenue KRW 938.18T, OP KRW 495.38T, Net Profit (Controlling) KRW 375.25T, PER 5.0x, ROE 32.8%, PBR 1.4x, EV/EBITDA 2.0x, DY 5.1%

🚀 2. [Market Opportunities & Business Outlook]

  • Prolonged Memory Supply-Demand Imbalance & Pricing Strength:
    • Structural undersupply environment projected to persist through at least 2027 despite advancing CapEx timelines
    • NAND pricing carries additional upside potential due to deprioritized capacity expansion plans
    • 2026F full-year assumptions: DRAM ASP +273%, B/G +21.5% / NAND ASP +292%, B/G +12%
  • 2H Earnings Acceleration & Divisional Forecasts:
    • 2H revenue and operating profit projected to grow +28.3% and +49.6% HoH, respectively (+52% HoH in semiconductor operating profit)
    • Commencing volume shipments of high-value applications including HBM4 and SOCAMM2, alongside mobile product launches and server processor segmentation
    • 2026F Operating Profit by Division: Semiconductor KRW 356.7T (DRAM KRW 269.6T, NAND KRW 91.7T, Non-memory -KRW 4.5T), Mobile KRW 4.9T, Display KRW 4.2T, Harman KRW 1.1T, Consumer Electronics KRW 0.1T
  • Foundry & Set Division Turnaround:
    • Foundry segment expects yield improvements and new order expansion starting in 2H
    • Set division anticipates profitability recovery once content revenues materialize post-market share expansion

📝 Editor’s Comment (Perspective)

The analyst views Samsung Electronics as a market leader capturing peak operating leverage from an extended structural memory shortage, driven by favorable product mix shifts toward premium memory. This perspective frames short-term share price consolidation as a timing opportunity within a structural upcycle, prioritizing valuation re-rating supported by long-term supply agreements and strengthened shareholder return programs.

To determine whether this investment thesis unfolds as anticipated, key verification checkpoints include the sustained growth in DRAM and NAND ASP and shipment volumes amid undersupply conditions through 2027, the timely execution of commercial shipments for HBM4 and SOCAMM2 alongside 2H foundry yield improvements, and the tangible execution of enhanced shareholder returns such as share cancellations and dividend payouts. These indicators can be tracked via subsequent quarterly earnings releases, official IR presentations, and regulatory filings on DART/KRX.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

글 탐색

Previous Post: [Research] Samsung Electronics (005930) – Mirae Asset | LPDDR5X Price Hikes · ASP Trajectory Upgrades · Target Price Upgrade / 2026-05-20
Next Post: [Research] LigaChem Biosciences (141080) – iM Securities | Clinical Data · Pipeline Progress · Tech Transfer / 2026-05-21

Related Posts

  • [Research] Samsung Electronics (005930) – Mirae Asset Securities | Operating Leverage · LTA Price Bands · High ROE Sustainability / 2026-04-06 Research
  • [Research] Samsung SDI (006400) – Hana Securities | North America JV Resolution · ESS Line Conversion · Earnings Estimate Upgrades / 2026-08-12 Research
  • [Research] Samsung Biologics (207940) – IBK Securities | Plant 5 Ramp-up · Resolution of Labor Risk · Annual Guidance Delivery / 2026-06-29 Research
  • [Research] Samsung Electro-Mechanics (009150) – IBK Securities | CapEx Projection · Non-IT MLCC · FC-BGA / 2026-05-04 Research
  • [Research] Samsung Electronics (005930) – Mirae Asset | LPDDR5X Price Hikes · ASP Trajectory Upgrades · Target Price Upgrade / 2026-05-20 Research
  • [Research] LIG D&A (079550) – Hana Securities | 1Q26 Earnings Beat · Backlog Re-rating · High-margin Follow-on Services / 2026-05-08 Research
  • [IR] Samsung Electro-Mechanics (009150) – Q2 2026 Earnings Presentation / 2026-07-30 IR Room
  • [Research] LIG D&A (079550) – Hanwha Investment & Securities | 4Q25 Review · Ghost Robotics Impairment Cleared · Margin Expansion / 2026-02-23 Research
  • [Research] LIG D&A (079550) – Daishin Securities | 1Q26 Review · Earnings Surprise · Export Diversification / 2026-05-08 Research
  • [Research] Samsung Biologics (207940) – Shinhan Securities | Wage Negotiation Factors · Rockville Ramp-up · Plant 6 Catalyst / 2026-07-01 Research
  • [Research] SK hynix (000660 / SKHY) – SK Securities | LTA · Earnings Visibility · Shareholder Returns / 2026-08-03 Research
  • [IR] Samsung Electronics (005930) – Q2 2024 Earnings Presentation / 2024-07-31 IR Room
  • [Research] KEPCO (015760 / KEP) – Eugene Investment & Securities | Nuclear Utilization Rate · Power Mix · Tariff Reform / 2026-08-13 Research
  • [Research] Alteogen (196170) – Hana Securities | New ALT-B4 Deal Signed · Qlex Prescription Surge · SC Conversion Acceleration / 2026-08-06 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme